Skip to main content

Table 3 Symptoms scores and quality of life scales

From: Bronchiectasis in renal transplant patients: a cross-sectional study

 

RT-B

n = 19

IB

n = 23

P value

Severity score

 FACEDa

2 (1–3)

2 (1–3)

1.000

 E-FACEDb

2 (0–3)

3 (1–4)

0.200

Symptoms score

 CASA-Q

  Cough symptom

75 (50–100)

42 (17–58)

0.0004

  Cough impact

82 (56–100)

50 (25–81)

0.019

  Sputum symptom

75 (50–100)

50 (33–67)

0.008

  Sputum impact

88 (71–100)

75 (38–83)

0.012

 HAD

  Anxiety (mean)

7 (3–10)

7 (3–10)

0.902

  Depression (mean)

6 (2–7)

6 (2–8)

0.805

Quality of life scales

 SGRQ

  Total score

38 (1–58)

38 (22–61)

0.219

 MOS SF-36

  Global physical score

36 (24–43)

36 (24–50)

0.745

  Global mental score

27 (5–47)

28 (16–44)

0.244

  1. Data are expressed as median (25th or 75th percentiles). p-value < 0.05 are considered as significant and highlighted in bold
  2. IB patients with idiopathic bronchiectasis, RT-B patients with renal transplantation and bronchiectasis
  3. CASA-Q: Cough And Sputum Assessment Questionnaire score assessing impact of cough and sputum production on daily activities, ranging from 0 to 100, with the highest score corresponding to a better quality of life; HAD: Hospital Anxiety and Depression Scale (HAD: a score between 0 and 7 for anxiety or depression domain meant no trouble, 8–10 suspected troubles, 11–21 confirmed trouble; SGQR: St George’s respiratory questionnaire (SGRQ) assessing symptoms and impact on daily activities with a score ranging from 0 to 100, that indicates the maximum impairment of quality of life; MOS SF-36: Medical Outcome Study Short Form 36 health survey, a multidimensional generic scale evaluating health status regardless of causal disease, sex, age, and treatment. A Physical Composite Score and a Mental Composite Score was calculated. A score of 100 indicates no impairment of quality of life [24]
  4. aFACED score incorporates five variables: forced expiratory volume in 1 s (FEV1) % predicted, age, chronic colonization by P. aeruginosa, extension of bronchiectasis by radiological assessment, and dyspnea
  5. bE-FACED score also includes the occurrence of exacerbations in the previous year